Skip to main content
NCBI home page
Sexually Transmitted Infections logoLink to Sexually Transmitted Infections
. 2004 Jun;80(3):219–222. doi: 10.1136/sti.2002.003491

Zafirlukast for severe recurrent vulvovaginal candidiasis: an open label pilot study

D White 1, A Vanthuyne 1, P Wood 1, J Ayres 1
PMCID: PMC1744832  PMID: 15170009

Abstract

Background: Recurrent vulvovaginal candidiasis (VVC) has been linked to allergic disease, particularly allergic rhinitis.

Objective: A pilot study to assess the possible use of the leukotriene receptor antagonist zafirlukast as a treatment for recurrent VVC.

Methods: 20 women with six or more symptomatic attacks of VVC in the past year (at least four proved microbiologically). Clinical atopy determined by the International Study for Asthma and Allergies in Childhood (ISAAC) questionnaire assessed blindly. Monitoring by daily symptom diary and self taken vaginal swabs. Treatment with zafirlukast 20 mg twice daily for 24 weeks or until three microbiologically confirmed episodes of VVC. Response assessed by daily symptom diary and self taken vaginal swabs. Subjective response scales for improvement, side effects, and change in other allergic disease completed when stopping treatment. Semistructured telephone interview 1 year after stopping medication.

Results: 14 patients (70%) reported a subjective response on the improvement response scale. Six (30%) showed a complete response with no further symptomatic attacks of VVC or negative swabs when symptomatic. Seven (37%) remained symptom free 18 months after entering the study—that is, 12 months after stopping therapy. 11 (58%) remained symptom free for at least 3 months after stopping therapy. This does not include one patient who remained symptom free but continued on zafirlukast because of an improvement in her asthma. There was no clear relation between response and atopic status. Six of nine atopic subjective responders reported improvements in other allergic symptoms. Side effects were minimal; one seemed clearly attributable to the drug.

Conclusion: Zafirlukast offers a potential new treatment for recurrent VVC that requires confirmation in controlled studies.

Full Text

The Full Text of this article is available as a PDF (59.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Birinci A., Saniç A., Durupinar B. Determination of minumum inhibitory concentrations of Candida species isolated from vaginal swab specimens by using broth macrodilution and E-test. J Chemother. 2001 Feb;13(1):43–46. doi: 10.1179/joc.2001.13.1.43. [DOI] [PubMed] [Google Scholar]
  2. El-Din S. S., Reynolds M. T., Ashbee H. R., Barton R. C., Evans E. G. An investigation into the pathogenesis of vulvo-vaginal candidosis. Sex Transm Infect. 2001 Jun;77(3):179–183. doi: 10.1136/sti.77.3.179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fidel P. L., Jr Vaginal candidiasis: review and role of local mucosal immunity. AIDS Patient Care STDS. 1998 May;12(5):359–366. doi: 10.1089/apc.1998.12.359. [DOI] [PubMed] [Google Scholar]
  4. Foxman B., Barlow R., D'Arcy H., Gillespie B., Sobel J. D. Candida vaginitis: self-reported incidence and associated costs. Sex Transm Dis. 2000 Apr;27(4):230–235. doi: 10.1097/00007435-200004000-00009. [DOI] [PubMed] [Google Scholar]
  5. Geiger A. M., Foxman B., Sobel J. D. Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, C glabrata and no candida. Genitourin Med. 1995 Oct;71(5):304–307. doi: 10.1136/sti.71.5.304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Giraldo P., von Nowaskonski A., Gomes F. A., Linhares I., Neves N. A., Witkin S. S. Vaginal colonization by Candida in asymptomatic women with and without a history of recurrent vulvovaginal candidiasis. Obstet Gynecol. 2000 Mar;95(3):413–416. doi: 10.1016/s0029-7844(99)00577-3. [DOI] [PubMed] [Google Scholar]
  7. Griffin M., Weiss J. W., Leitch A. G., McFadden E. R., Jr, Corey E. J., Austen K. F., Drazen J. M. Effects of leukotriene D on the airways in asthma. N Engl J Med. 1983 Feb 24;308(8):436–439. doi: 10.1056/NEJM198302243080807. [DOI] [PubMed] [Google Scholar]
  8. Kudelko N. M. Allergy in chronic monilial vaginitis. Ann Allergy. 1971 May;29(5):266–267. [PubMed] [Google Scholar]
  9. Lipworth B. J. Emerging role of antileukotriene therapy in allergic rhinitis. Clin Exp Allergy. 2001 Dec;31(12):1813–1821. doi: 10.1046/j.1365-2222.2001.01202.x. [DOI] [PubMed] [Google Scholar]
  10. Lockhart S. R., Reed B. D., Pierson C. L., Soll D. R. Most frequent scenario for recurrent Candida vaginitis is strain maintenance with "substrain shuffling": demonstration by sequential DNA fingerprinting with probes Ca3, C1, and CARE2. J Clin Microbiol. 1996 Apr;34(4):767–777. doi: 10.1128/jcm.34.4.767-777.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Marrazzo Jeanne. Vulvovaginal candidiasis. Clin Evid. 2002 Jun;(7):1784–1796. [PubMed] [Google Scholar]
  12. Moraes P. S. Recurrent vaginal candidiasis and allergic rhinitis: a common association. Ann Allergy Asthma Immunol. 1998 Aug;81(2):165–169. doi: 10.1016/S1081-1206(10)62804-9. [DOI] [PubMed] [Google Scholar]
  13. Moraes P. S. Recurrent vaginal candidiasis and allergic rhinitis: a common association. Ann Allergy Asthma Immunol. 1998 Aug;81(2):165–169. doi: 10.1016/S1081-1206(10)62804-9. [DOI] [PubMed] [Google Scholar]
  14. Moraes P. S., de Lima Goiaba S., Taketomi E. A. Candida albicans allergen immunotherapy in recurrent vaginal candidiasis. J Investig Allergol Clin Immunol. 2000 Sep-Oct;10(5):305–309. [PubMed] [Google Scholar]
  15. Nelson A. L. The impact of contraceptive methods on the onset of symptomatic vulvovaginal candidiasis within the menstrual cycle. Am J Obstet Gynecol. 1997 Jun;176(6):1376–1380. doi: 10.1016/s0002-9378(97)70362-4. [DOI] [PubMed] [Google Scholar]
  16. Reiss T. F., Chervinsky P., Dockhorn R. J., Shingo S., Seidenberg B., Edwards T. B. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med. 1998 Jun 8;158(11):1213–1220. doi: 10.1001/archinte.158.11.1213. [DOI] [PubMed] [Google Scholar]
  17. Rigg D., Miller M. M., Metzger W. J. Recurrent allergic vulvovaginitis: treatment with Candida albicans allergen immunotherapy. Am J Obstet Gynecol. 1990 Feb;162(2):332–336. doi: 10.1016/0002-9378(90)90380-p. [DOI] [PubMed] [Google Scholar]
  18. Rosedale N., Browne K. Hyposensitisation in the management of recurring vaginal candidiasis. Ann Allergy. 1979 Oct;43(4):250–253. [PubMed] [Google Scholar]
  19. Samuelsson B., Borgeat P., Hammarström S., Murphy R. C. Introduction of a nomenclature: leukotrienes. Prostaglandins. 1979 Jun;17(6):785–787. doi: 10.1016/0090-6980(79)90052-2. [DOI] [PubMed] [Google Scholar]
  20. Smith P. D., Lamerson C. L., Banks S. M., Saini S. S., Wahl L. M., Calderone R. A., Wahl S. M. Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans. J Infect Dis. 1990 May;161(5):999–1005. doi: 10.1093/infdis/161.5.999. [DOI] [PubMed] [Google Scholar]
  21. Sobel J. D., Faro S., Force R. W., Foxman B., Ledger W. J., Nyirjesy P. R., Reed B. D., Summers P. R. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998 Feb;178(2):203–211. doi: 10.1016/s0002-9378(98)80001-x. [DOI] [PubMed] [Google Scholar]
  22. Sobel J. D., Kapernick P. S., Zervos M., Reed B. D., Hooton T., Soper D., Nyirjesy P., Heine M. W., Willems J., Panzer H. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol. 2001 Aug;185(2):363–369. doi: 10.1067/mob.2001.115116. [DOI] [PubMed] [Google Scholar]
  23. Spector S. L., Smith L. J., Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med. 1994 Sep;150(3):618–623. doi: 10.1164/ajrccm.150.3.8087328. [DOI] [PubMed] [Google Scholar]
  24. Suissa S., Dennis R., Ernst P., Sheehy O., Wood-Dauphinee S. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997 Feb 1;126(3):177–183. doi: 10.7326/0003-4819-126-3-199702010-00001. [DOI] [PubMed] [Google Scholar]
  25. Suissa S., Dennis R., Ernst P., Sheehy O., Wood-Dauphinee S. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997 Feb 1;126(3):177–183. doi: 10.7326/0003-4819-126-3-199702010-00001. [DOI] [PubMed] [Google Scholar]
  26. Vazquez J. A., Sobel J. D., Demitriou R., Vaishampayan J., Lynch M., Zervos M. J. Karyotyping of Candida albicans isolates obtained longitudinally in women with recurrent vulvovaginal candidiasis. J Infect Dis. 1994 Dec;170(6):1566–1569. doi: 10.1093/infdis/170.6.1566. [DOI] [PubMed] [Google Scholar]
  27. Vichyanond P., Sunthornchart S., Singhirannusorn V., Ruangrat S., Kaewsomboon S., Visitsunthorn N. Prevalence of asthma, allergic rhinitis and eczema among university students in Bangkok. Respir Med. 2002 Jan;96(1):34–38. doi: 10.1053/rmed.2001.1202. [DOI] [PubMed] [Google Scholar]

Articles from Sexually Transmitted Infections are provided here courtesy of BMJ Publishing Group

RESOURCES